Targeting Tumor Microenvironment for Cancer Therapy
Open accessThe DOI matches its Crossref record; 209 of the 212 references it cites were found in a registry or an index.
Abstract
Cancer development is highly associated to the physiological state of the tumor microenvironment (TME). Despite the existing heterogeneity of tumors from the same or from different anatomical locations, common features can be found in the TME maturation of epithelial-derived tumors. Genetic alterations in tumor cells result in hyperplasia, uncontrolled growth, resistance to apoptosis, and metabolic shift towards anaerobic glycolysis (Warburg effect). These events create hypoxia, oxidative stress and acidosis within the TME triggering an adjustment of the extracellular matrix (ECM), a response from neighbor stromal cells (e.g., fibroblasts) and immune cells (lymphocytes and macrophages), inducing angiogenesis and, ultimately, resulting in metastasis. Exosomes secreted by TME cells are central players in all these events. The TME profile is preponderant on prognosis and impacts efficacy of anti-cancer therapies. Hence, a big effort has been made to develop new therapeutic strategies towards a more efficient targeting of TME. These efforts focus on: (i) therapeutic strategies targeting TME components, extending from conventional therapeutics, to combined therapies and nanomedicines; and (ii) the development of models that accurately resemble the TME for bench investigations, including tumor-tissue explants, “tumor on a chip” or multicellular tumor-spheroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Main properties of in vitro 2D and 3D culture systems [187,188]. CAF, Cancer-associated fibroblast; ECM, Extracellular matrix.](https://figures.cochat.ai/paper-figures/5beab1962bf5470fbdf9b87661e2bff6/targeting-tumor-microenvironment-for-cancer-therapy-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dense ECM, abnormal vasculature, and an acidified environment all contribute to decreased drug penetration [83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the microenvironment of healthy tissue, the TME has augmented deposition of proteins such as collagen and fibronectin, high cytokine levels, increased proportion of fibroblasts and immune cells, and is immunosuppressive [82,83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“agents that degrade and/or deconstruct the ECM should be used cautiously, as they may lead to the release of factors that promote tumor progression and induce metastasis [83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Concerning the therapeutic outcome of such drugs, although they showed to improve patient survival, it has not been as great as expected, mostly related to the fact that patients stop responding or do not respond at all to these therapies, or even due to the side effects, for instance, the increased risk of arterial t…”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“While some tumors present few signals of inflammation, others show a high number of immune cells either at the periphery or infiltrated within the tumor [70,71].”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 3×
“Epithelial tumors display common features that allow for the setting of hallmarks that define cancer progression [7,8].”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“For this reason, tumors are frequently regarded as “wounds that never heal” [7,92].”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Research works printed but not linked: 1
- Larson B. 3D cell culture: A review of current techniques BioTek 2015 6 1 10
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“Hypoxia induces changes in gene expression and subsequent proteomic changes that have many important effects on various cellular and physiological functions, ultimately limiting patient prognosis [15].”
BackgroundThe updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Role of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 442
Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research
Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440
“Many factors present in the TME, including transforming growth factor beta (TGF-β), cytokines (IL-10 and IL-1β), members of the VEGF, plateled-derived growth factor (PDGF), FGF, angiopoietin families, Bv8/PROK2, and hypoxia-inducible factor (HIF)-1α, provide molecular support to tumor growth and progression [27–30].”
BackgroundInfluentialAlmansour, N. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.836417 · Cited by 397
Cancer associated-fibroblast-derived exosomes in cancer progression
Li, C., Teixeira, A. F., Zhu, H.-J., & ten Dijke, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01463-y · Cited by 336
Tumor microenvironment in glioblastoma: Current and emerging concepts
Sharma, P., Aaroe, A., Liang, J., & Puduvalli, V. K. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad009 · Cited by 314
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Tumor microenvironment promotes breast cancer chemoresistance
Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04222-w · Cited by 289
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Yu, J., Song, Y., & Tian, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00876-4 · Cited by 269
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
Argilés, J. M., López-Soriano, F. J., Stemmler, B., & Busquets, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00734-5 · Cited by 246
Tumor microenvironment components: Allies of cancer progression
Ribeiro Franco, P. I., Rodrigues, A. P., de Menezes, L. B., & Pacheco Miguel, M. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152729 · Cited by 237
Qin, W., Wang, C., Ma, Y., Shen, M., Li, J., Jiao, K., Tay, F. R., & Niu, L. (2020) · Advanced Materials · doi:10.1002/adma.201907833 · Cited by 232
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, M.-A., Lagopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 220
Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment
Semmler, M. L., Bekeschus, S., Schäfer, M., Bernhardt, T., Fischer, T., Witzke, K., Seebauer, C., Rebl, H., Grambow, E., Vollmar, B., et al. (2020) · Cancers · doi:10.3390/cancers12020269 · Cited by 220
Fu, S., Yang, R., Ren, J., Liu, J., Zhang, L., Xu, Z., Kang, Y., & Xue, P. (2021) · ACS Nano · doi:10.1021/acsnano.1c03128 · Cited by 217
Designing Stimuli‐Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment
Ovais, M., Mukherjee, S., Pramanik, A., Das, D., Mukherjee, A., Raza, A., & Chen, C. (2020) · Advanced Materials · doi:10.1002/adma.202000055 · Cited by 215
Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
Hayes, C., Donohoe, C. L., Davern, M., & Donlon, N. E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.021 · Cited by 213
Zhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
Weth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02502-9 · Cited by 197
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
El-Tanani, M., Rabbani, S. A., Babiker, R., Rangraze, I., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A., Rizzo, M., El-Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 202
Multi‐Functional Liposome: A Powerful Theranostic Nano‐Platform Enhancing Photodynamic Therapy
Cheng, X., Gao, J., Ding, Y., Lu, Y., Wei, Q., Cui, D., Fan, J., Li, X., Zhu, E., Lu, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202100876 · Cited by 208
Small‐Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery
Li, G., Sun, B., Li, Y., Luo, C., He, Z., & Sun, J. (2021) · Small · doi:10.1002/smll.202101460 · Cited by 205
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 195
Anticancer Activity of Natural and Synthetic Chalcones
Constantinescu, T., & Lungu, C. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111306 · Cited by 187
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth
Munir, M. T., Kay, M. K., Kang, M. H., Rahman, M. M., Al-Harrasi, A., Choudhury, M., Moustaid-Moussa, N., Hussain, F., & Rahman, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126526 · Cited by 188
The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041565 · Cited by 189
The mechanism of Warburg effect-induced chemoresistance in cancer
Liu, C., Jin, Y., & Fan, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698023 · Cited by 177
Pathological angiogenesis and inflammation in tissues
Jeong, J.-H., Ojha, U., & Lee, Y. M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01287-2 · Cited by 174
Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer
Mizuno, R., Kawada, K., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246254 · Cited by 174
Naoi, M., Wu, Y., Shamoto-Nagai, M., & Maruyama, W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102451 · Cited by 171
Impact of cancer metabolism on therapy resistance – Clinical implications
Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento-Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 164
Luo, Z.-W., Xia, K., Liu, Y.-W., Liu, J.-H., Rao, S.-S., Hu, X.-K., Chen, C.-Y., Xu, R., Wang, Z.-X., & Xie, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s304515 · Cited by 162
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
“that interfere with CAF/TAM interactions, and their combinations hereof, are highly prioritized in experimental clinical regimens that are aimed at modulating the TME (8).”
BackgroundThe Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146
M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942
Wei, K., Ma, Z., Yang, F., Zhao, X., Jiang, W., Pan, C., Li, Z., Pan, X., He, Z., Xu, J., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.045 · Cited by 146
Zhang, C., Qin, C., Dewanjee, S., Bhattacharya, H., Chakraborty, P., Jha, N. K., Gangopadhyay, M., Jha, S. K., & Liu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01932-0 · Cited by 148
Spatial oncology: Translating contextual biology to the clinic
Gong, D. H., Arbesfeld-Qiu, J. M., Perrault, E. N., Bae, J. W., & Hwang, W. L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.001 · Cited by 160
Detection of cell–cell interactions via photocatalytic cell tagging
Oslund, R. C., Reyes-Robles, T., White, C. H., Tomlinson, J. H., Crotty, K. A., Bowman, E. P., Chang, D., Peterson, V. M., Li, L., Frutos, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01044-0 · Cited by 133
Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy
Lorenc, T., Klimczyk, K., Michalczewska, I., Słomka, M., Kubiak-Tomaszewska, G., & Olejarz, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062118 · Cited by 143
dos Santos, D. Z., de Souza, J. C., Pimenta, T. M., Martins, B. D. S., Ribeiro, R. S., Butzene, S. M. S., Tessarolo, N. G., Junior, P. C. M. L., Silva, I. V., & Rangel, L. B. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01178-1 · Cited by 149
Role of Exosomes in Prostate Cancer Metastasis
Akoto, T., & Saini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073528 · Cited by 136
Current Understanding of Flavonoids in Cancer Therapy and Prevention
Farhan, M., Rizvi, A., Aatif, M., & Ahmad, A. (2023) · Metabolites · doi:10.3390/metabo13040481 · Cited by 136
Ding, B., Zheng, P., Tan, J., Chen, H., Meng, Q., Li, J., Li, X., Han, D., Li, Z., Ma, X., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202307706 · Cited by 134
Radisky, E. S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107347 · Cited by 147
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 120
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Fleming, B., Edison, P., & Kenny, L. M. (2023) · BMJ · doi:10.1136/bmj-2022-071726 · Cited by 142
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment
Li, J., & Burgess, D. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.008 · Cited by 123
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Singh, A. K., Dees, S., & Grewal, I. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01225-5 · Cited by 122
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression
Huang, Q., Wu, M., Wu, X., Zhang, Y., & Xia, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188761 · Cited by 138
Combinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 128
Huang, M., Fu, M., Wang, J., Xia, C., Zhang, H., Xiong, Y., He, J., Liu, J., Liu, B., Pan, S., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114527 · Cited by 133
Li, J., Zhang, G., Liu, C., Xiang, X., Le, M. T. N., Sethi, G., Wang, L., Goh, B.-C., & Ma, Z. (2021) · Theranostics · doi:10.7150/thno.64096 · Cited by 121
Setargew, Y. F. I., Wyllie, K., Grant, R. D., Chitty, J. L., & Cox, T. R. (2021) · Cancers · doi:10.3390/cancers13030491 · Cited by 120
Stimulus-Controlled Anion Binding and Transport by Synthetic Receptors
de Jong, J., Bos, J. E., & Wezenberg, S. J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00039 · Cited by 113
Targeting the tumor microenvironment: Potential strategy for cancer therapeutics
Babar, Q., Saeed, A., Tabish, T. A., Sarwar, M., & Thorat, N. D. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166746 · Cited by 125
Role of Mitochondria in Cancer Stem Cell Resistance
García-Heredia, J. M., & Carnero, A. (2020) · Cells · doi:10.3390/cells9071693 · Cited by 111
Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment
Fan, H., & Guo, Z. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215027 · Cited by 107
The tumour microenvironment as an integrated framework to understand cancer biology
Burgos-Panadero, R., Lucantoni, F., Gamero-Sandemetrio, E., Cruz-Merino, L. D. L., Álvaro, T., & Noguera, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.010 · Cited by 105
Photodynamic Therapy and the Biophysics of the Tumor Microenvironment
Sorrin, A. J., Ruhi, M. K., Ferlic, N. A., Karimnia, V., Polacheck, W. J., Celli, J. P., Huang, H., & Rizvi, I. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13209 · Cited by 109
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 113
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 107
Immune Landscape of Thyroid Cancers: New Insights
Menicali, E., Guzzetti, M., Morelli, S., Moretti, S., & Puxeddu, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.637826 · Cited by 111
Cheng, Y., Wang, S. B., Liu, J. H., Jin, L., Liu, Y., Li, C. Y., Su, Y., Liu, Y. R., Sang, X., Wan, Q., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12865 · Cited by 108
Deciphering Tumor Ecosystems at Super-Resolution from Spatial Transcriptomics with Tesla
Hu, J., Coleman, K., Zhang, D., Lee, E. B., Kadara, H. N., Wang, L., & Li, M. (2022) · Cell Systems · doi:10.1016/j.cels.2023.03.008 · Cited by 117
Nicolini, A., Ferrari, P., & Biava, P. M. (2021) · Cancers · doi:10.3390/cancers13040822 · Cited by 102
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 109
Role of Exosomes for Delivery of Chemotherapeutic Drugs
Gebeyehu, A., Kommineni, N., Meckes, D. G., & Sachdeva, M. S. (2021) · Critical Reviews™ in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2021036301 · Cited by 87
Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system
Tian, C., Zheng, S., Liu, X., & Kamei, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01552-0 · Cited by 101
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 110
Li, C., & Hua, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897366 · Cited by 95
Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy
Lôbo, G. C. N. B., Paiva, K. L. R., Silva, A. L. G., Simões, M. M., Radicchi, M. A., & Báo, S. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081167 · Cited by 101
DNA Logic Circuits for Cancer Theranostics
Chen, J., Fu, S., Zhang, C., Liu, H., & Su, X. (2022) · Small · doi:10.1002/smll.202108008 · Cited by 98
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments
Tian, W., Liu, Y., Cao, C., Zeng, Y., Pan, Y., Liu, X., Peng, Y., & Wu, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777018 · Cited by 107
From Warburg effect to Reverse Warburg effect; the new horizons of anti-cancer therapy
Benny, S., Mishra, R., Kumar, M. K. M., & Aneesh, T. P. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110216 · Cited by 91
Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy
Thakur, N., Thakur, S., Chatterjee, S., Das, J., & Sil, P. C. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.597806 · Cited by 92
The paradigm of drug resistance in cancer: an epigenetic perspective
Adhikari, S., Bhattacharya, A., Adhikary, S., Singh, V., Gadad, S. S., Roy, S., & Das, C. (2022) · Bioscience Reports · doi:10.1042/bsr20211812 · Cited by 96
Collagen architecture and signaling orchestrate cancer development
Su, H., & Karin, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.002 · Cited by 94
Privat‐Maldonado, A., Bengtson, C., Razzokov, J., Smits, E., & Bogaerts, A. (2019) · Cancers · doi:10.3390/cancers11121920 · Cited by 91
The acidic tumour microenvironment: Manipulating the immune response to elicit escape
Worsley, C. M., Veale, R. B., & Mayne, E. S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.01.014 · Cited by 96
Hyaluronan Receptors as Mediators and Modulators of the Tumor Microenvironment
Carvalho, A. M., Reis, R. L., & Pashkuleva, I. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202118 · Cited by 93
Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics
Ulldemolins, A., Seras‐Franzoso, J., Andrade, F., Rafael, D. F. D. S., Abasolo, I., Gener, P., & Schwartz, S. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.59 · Cited by 119
Mitochondrial dysfunction-targeted nanosystems for precise tumor therapeutics
Ma, Z., Han, H., & Zhao, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121947 · Cited by 90
Tumor-Associated Neutrophils in Colorectal Cancer Development, Progression and Immunotherapy
Zheng, W., Wu, J., Peng, Y., Sun, J., Cheng, P., & Huang, Q. (2022) · Cancers · doi:10.3390/cancers14194755 · Cited by 94
Targeting tumor vascularization: promising strategies for vascular normalization
Zheng, R., Li, F., Li, F., & Gong, A. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03701-8 · Cited by 93
Low-Temperature Plasma Techniques in Biomedical Applications and Therapeutics: An Overview
Karthik, C., Chand, S., & Thomas, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010524 · Cited by 94
Metadata
- Authors
- Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R.
- Affiliations
- UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa. Campus de Caparica, 2829-516 Caparica, Portugal
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Baptista, Pedro V.
- Fernandes, Alexandra R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 840
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6413095
- OpenAlex
- W2913062750
- Cited by
- 1,187
- References
- 212
- Citations by year
- 2026: 76 · 2025: 134 · 2024: 156 · 2023: 229 · 2022: 186 · 2021: 216 · 2020: 139 · 2019: 47
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Ministério da Ciência, Tecnologia e Ensino Superior (UID/Multi/04378/2019, SFRH/BPD/124612/2016)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- tumor microenvironment, cancer therapy, Warburg effect, tumor hypoxia, oxidative stress, extracellular matrix, tumor stromal cells, tumor-associated macrophages, angiogenesis, metastasis, exosomes, nanomedicine, combination therapy, tumor models, tumor-on-a-chip, tumor spheroids
- MeSH terms
- Animals, Humans, Models, Biological, Neoplasms, Neovascularization, Pathologic, Nanomedicine, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.